

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Connectyx Technologies Holdings Group, Inc.

A Florida Corporation

1825 NW Corporate Blvd., Suite 110
Boca Raton, FL 33431

SIC – 8731/8733

Quarterly Report

For the Period Ending: June 30, 2020 (the “Reporting Period”)

As of June 30, 2020, the number of shares outstanding of our Common Stock was:

322,800,327

As of March 31, 2020, the number of shares outstanding of our Common Stock was:

322,800,327

As of December 31, 2019, the number of shares outstanding of our Common Stock was:

322,800,327

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control of the company has occurred over this reporting period:

Yes: No:

1) Name of the issuer and its predecessors (if any)

Connectyx Technologies Holdings Group, Inc., herein referred to as “CTYX” or the “Company.”

The company was formerly known as: Storage Innovation Technologies, Inc. until 10-07; National Boston Medical, Inc. until 5-04; Fragrance Express, Inc. until 10-98; Growth Industries, Inc. until 7-98

The Company was originally incorporated on June 29, 1995, in the State of Nevada; the Company, as of October 31, 2007, was reincorporated in the State of Florida and is active in the state.

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

2) Security Information

Trading symbol: CTYX
Exact title and class of securities outstanding: Common Stock
 (“Common Stock”) CUSIP: 20786Q209
Par or stated value: \$0.001

Total shares authorized: 1,100,000,000 as of date: July 30, 2020
Total shares outstanding: 322,800,327 as of date: August 6, 2020
Number of shares in the public float: 188,707,258 as of date: August 6, 2020
Total number of shareholders of record: 165 as of date: August 6, 2020

Additional class of securities that are publicly traded (if any):

N/A

Transfer Agent

Name: Issuer Direct Corporation
Address: One Glenwood Ave, Suite 1001
Address 2: Raleigh, NC 27603
Phone: +1 (919) 481-4000
Email: info@issuereirect.com

Is the Transfer Agent registered under the Exchange Act?

Yes: No:

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

3) Issuance History

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Number of Shares outstanding as of <u>12/31/2017</u>		<u>Opening Balance:</u> Common: 322,800,327 Series A Preferred: 34,109,750 Series B Preferred: 293,000		*Right-click the rows below and select "Insert" to add rows as needed.					
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
Shares Outstanding on <u>06/30/2020:</u>		<u>Ending Balance:</u> Common: 322,800,327 Preferred Series A: 34,109,750 Preferred Series B: 293,000							

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
- IFRS

B. The financial statements for this reporting period were prepared by (name of individual):

Name: Dr. Barry A. Ginsberg
 Title: Chief Strategy Officer
 Relationship to Issuer: Director

The unaudited financial statements for the quarter ended June 30, 2020 are included at the end of this report.

5) Issuer's Business, Products and Services

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Connectyx Technologies Holdings Group, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company is leveraging management's experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company's business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference. N/A

C. Describe the issuers' principal products or services, and their markets

Connectyx Technologies Holdings Group, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company's business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

6) Issuers facilities

The Company utilizes virtual office space at a cost of \$99 per month.

7) **Officers Directors and Control Persons**

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Paul M. Michaels (1)	Officer and Director	Boca Raton, FL	21,653,800	Series A Preferred	63.5 %	See note (1), below
Barry A. Ginsberg (1)	Officer and Director	Boca Raton, FL	21,653,800	Series A Preferred	63.5%	See note (1), below
Brandon Michaels	Director	Boca Raton, FL	--	N/A	--	
Al Forcella	5% Holder	Stuart, FL	3,600,000	Series A Preferred	10.6%	
William Carlson	5% Holder	Stuart, FL	2980,000	Series A Preferred	8.7%	
Jeff Frankel	5% Holder	Stuart, FL	2,884,750	Series A Preferred	8.5%	
Jose Bardelas	5% Holder	High Point, NC	29,018,212	Common	8.99%	

(1) SunMed Advisors LLC purchased the Series A Preferred stock of former President Jon Pevzner and Amanda Schuman on February 24, 2020. Pevzner resigned as an officer and director of the Company on February 24, 2020. At that time Paul M. Michaels was appointed Interim CEO and Director. Dr. Barry A. Ginsberg and Brandon Michaels were also appointed to the Board of Directors. SunMed Advisors LLC is beneficially owned by Paul M. Michaels and Dr. Barry A. Ginsberg.

8) Legal/Disciplinary History

A. Criminal and legal proceedings of Officers, Directors and Control Persons.

Neither of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject.

None.

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Jonathan D. Leinwand
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18851 NE 29th Avenue, Suite 1011
Address 2: Aventura, FL 33180
Phone: +1 954-903-7856
Email: jonathan@jdlpa.com

Accountant: N/A

Name:
Firm:
Address 1:
Address 2:
Phone:

Investor Relations Consultant: N/A

Other Service Providers: N/A

10) Issuer Certification

Principal Executive Officer:

I, Paul M. Michaels certify that:

1. I have reviewed this quarterly statement of Connectyx Technologies Holdings Group, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: August 12, 2020
Signature: /s/ Paul M. Michaels
Name: Paul M. Michaels
Title: CEO and Director

Principal Financial Officer:

I, Barry A. Ginsberg certify that:

1. I have reviewed this quarterly statement of Connectyx Technologies Holdings Group, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: August 12, 2020
Signature: /s/Barry A. Ginsberg
Name: Barry A. Ginsberg
Title: CSO and Director

INDEX TO UNAUDITED FINANCIAL STATEMENTS

Balance Sheets	F-2
Statements of Operations	F-3
Statement of Stockholders' Equity	F-4
Statements of Cash Flows	F-5
Notes to Financial Statements	F-6

Connectyx Technologies Holdings Group, Inc.
Balance Sheets
(Unaudited)

	<u>June 30,</u> <u>2020</u>	<u>December</u> <u>31, 2019</u>
ASSETS		
CURRENT ASSETS		
Cash	\$ -	\$ -
Accounts receivable, net	-	-
Prepaid expenses	-	-
Total current assets	<u>-</u>	<u>-</u>
FIXED ASSETS		
Property and equipment	81,515	81,515
Accumulated depreciation	<u>(78,912)</u>	<u>(78,648)</u>
Total Fixed Assets	<u>2,603</u>	<u>2,867</u>
OTHER ASSETS		
Intangible assets, net of amortization	<u>34,522</u>	<u>36,908</u>
Total other assets	<u>34,522</u>	<u>36,908</u>
Total Assets	<u>\$ 37,125</u>	<u>\$ 39,775</u>
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
CURRENT LIABILITIES		
Accounts payable and accrued liabilities	\$ 450	\$ 397,103
Related party short term loans	<u>31,734</u>	<u>-</u>
Total current liabilities	<u>32,184</u>	<u>397,103</u>
Total Liabilities	<u>32,184</u>	<u>397,103</u>
Commitments and Contingencies	-	-
STOCKHOLDERS' EQUITY (DEFICIT)		
Preferred stock, \$0.0001 par value, authorized 205,000,000 shares, 34,109,750 Series A and 293,000 Series B shares issued and outstanding	3,440	3,440
Common stock, \$0.001 par value, authorized 1,100,000,000 shares; 322,800,327 shares issued and outstanding	322,800	322,800
Additional paid-in capital	3,023,567	3,023,567
Treasury stock	(9,900)	(9,900)
Accumulated deficit	<u>(3,334,966)</u>	<u>(3,697,235)</u>
Total stockholders' equity (deficit)	<u>4,941</u>	<u>(357,328)</u>
Total Liabilities and Stockholders' Equity	<u>\$ 37,125</u>	<u>\$ 39,775</u>

The accompanying notes are an integral part of the financial statements

Connectyx Technologies Holdings Group, Inc.
Statements of Operations
(Unaudited)

Three and six months ended June 30,

	<u>Three months ended June 30,</u>		<u>Six months ended June 30,</u>	
	2020	2019	2020	2019
REVENUES, net	\$ -	\$ -	\$ -	\$ -
COST OF REVENUES	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
GROSS MARGIN	-	-	-	-
OPERATING EXPENSES:				
General and administrative expenses	17,652	-	32,184	-
Interest expense	-	3,971	-	7,941
Bad debt expense	-	-	-	8,581
Gain of debt forgiveness	(17,602)	-	(397,103)	-
Depreciation and amortization	<u>1,325</u>	<u>1,325</u>	<u>2,650</u>	<u>2,650</u>
Total expenses	<u>1,375</u>	<u>5,296</u>	<u>(362,269)</u>	<u>19,172</u>
Net income (loss)	<u>\$ (1,375)</u>	<u>\$ (5,296)</u>	<u>\$ 362,269</u>	<u>\$ (19,172)</u>
Income (loss) per weighted average common share	<u>\$0.0000</u>	<u>\$0.0000</u>	<u>\$0.0011</u>	<u>\$(0.0001)</u>
Number of weighted average common shares outstanding	<u>322,800,327</u>	<u>322,800,327</u>	<u>322,800,327</u>	<u>322,800,327</u>

The accompanying notes are an integral part of the financial statements

Connectyx Technologies Holdings Group, Inc.
Statement of Stockholders' Equity (Deficit)
(Unaudited)

Three and six months ended June 30,

	Number of Shares		Par Value		Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Common	Preferred	Common	Preferred				
BALANCE, January 1, 2020	322,800,327	34,402,750	\$ 322,800	\$3,440	\$(9,900)	\$ 3,023,567	\$ (3,697,235)	\$ (357,328)
Net income	-	-	-	-	-	-	363,644	363,644
BALANCE, March 31, 2020	322,800,327	34,402,750	322,800	3,440	(9,900)	3,023,567	(3,333,591)	6,316
Net loss	-	-	-	-	-	-	(1,375)	(1,375)
BALANCE, June 30, 2020	<u>322,800,327</u>	<u>34,402,750</u>	<u>\$ 322,800</u>	<u>\$ 3,440</u>	<u>\$(9,900)</u>	<u>\$ 3,023,567</u>	<u>\$ (3,334,966)</u>	<u>\$ 4,941</u>

Connectyx Technologies Holdings Group, Inc.
Statement of Stockholders' Equity (Deficit)
(Unaudited)

Three and six months ended June 30,

	Number of Shares		Par Value		Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Common	Preferred	Common	Preferred				
BALANCE, January 1, 2019	322,800,327	34,402,750	\$ 322,800	\$3,440	\$(9,900)	\$ 3,023,567	\$ (4,029,188)	\$ (689,281)
Net loss	-	-	-	-	-	-	(13,877)	(13,877)
BALANCE, March 31, 2019	322,800,327	34,402,750	322,800	3,440	(9,900)	3,023,567	(4,043,065)	(703,158)
Net loss	-	-	-	-	-	-	(5,296)	(5,296)
BALANCE, June 30, 2019	<u>322,800,327</u>	<u>34,402,750</u>	<u>\$ 322,800</u>	<u>\$ 3,440</u>	<u>\$(9,900)</u>	<u>\$ 3,023,567</u>	<u>\$ (4,048,361)</u>	<u>\$ (708,454)</u>

The accompanying notes are an integral part of the financial statements

Connectyx Technologies Holdings Group, Inc.
Statements of Cash Flows
(Unaudited)
Six months ended June 30,

	2020	2019
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income (loss)	\$362,269	(\$19,172)
Adjustments to reconcile net loss to net cash used by operating activities:		
Depreciation and amortization	2,650	2,650
Gain on debt forgiveness	(397,103)	-
Bad debt expense	-	8,581
Changes in operating assets and liabilities		
Decrease (increase) in accounts receivable	-	-
Decrease in inventory	-	-
Increase (decrease) in accounts payable	450	-
Increase in accrued expenses	-	7,941
	<u>(31,734)</u>	<u>-</u>
Net cash provided by (used in) operating activities		
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of fixed assets	-	-
	<u>-</u>	<u>-</u>
Net cash (used in) investing activities		
	<u>-</u>	<u>-</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Common shares issued for cash	-	-
Payments on related party loans	-	-
Cash received from related party loans	31,734	-
	<u>31,734</u>	<u>-</u>
Net cash (used in) provided by financing activities		
	<u>31,734</u>	<u>-</u>
Net (decrease) increase in cash	<u>-</u>	<u>-</u>
CASH, beginning of period	<u>-</u>	<u>-</u>
CASH, end of period	<u>\$ -</u>	<u>\$ -</u>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Interest paid in cash	<u>\$ -</u>	<u>\$ -</u>
Income taxes paid in cash	<u>\$ -</u>	<u>\$ -</u>

The accompanying notes are an integral part of the financial statements

Connectyx Technologies Holdings Group, Inc.
Notes to Financial Statements
(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

(a) **The Company** Connectyx Technologies Holdings Group, Inc. (CTYX) is a Florida corporation which conducts business from its headquarters in Boca Raton, Florida. Connectyx Technologies Holdings Group, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company's business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

NOTE 2 - BASIS OF PRESENTATION

a) Statement of Compliance

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") as issued by the Financial Accounting Standards Board ("FASB").

b) Basis of Measurement

The Company's financial statements have been prepared on the historical cost basis.

c) Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following summarize the more significant accounting and reporting policies and practices of the Company:

(a) **Net income (loss) per share** Basic loss per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period.

(b) **Property and equipment** All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.

(c) **Income Taxes** Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes.

Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

Connectyx Technologies Holdings Group, Inc.
Notes to Financial Statements
(Unaudited)

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

(d) Cash and equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents.

(e) Financial Instruments Financial Accounting Standards Board's (FASB) Accounting Standards Codification (ASC) 825, Disclosures about Fair Value of Financial Instruments, requires disclosures of the fair value of financial instruments. The carrying value of the Company's current financial instruments, which include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities and shareholder loan, approximates their fair values because of the short-term maturities of these instruments.

The Company initially measures its financial instrument at fair value, except for certain non-arm's length transactions.

The Company subsequently measures all its financial assets and financial liabilities at amortized cost, except for investments in equity instruments that are quoted in an active market, which are measured at fair value. Changes in fair value are recognized in earnings for the period in which they occur.

Financial liabilities include accounts payable and accrued liabilities.

Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in earnings for the period. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in earnings for the period.

(f) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

(g) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

(h) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any.

Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives.

Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.

Connectyx Technologies Holdings Group, Inc.
Notes to Financial Statements
(Unaudited)

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

(i) **Recent Accounting Pronouncements** The Company has considered recent accounting pronouncements during the preparation of these financial statements.

NOTE 4 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company's financial position and operating results raise substantial doubt about the Company's ability to continue as a going concern, as reflected by the net income of \$362,269 resulting from debt forgiveness accumulated through June 30, 2020 and the minimal working capital position. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to grow its operations

NOTE 5 - RELATED PARTY TRANSACTIONS

From time to time the Company may enter into non-arms length transactions with related parties. These transactions will be valued at historical cost with no value increase given. During 2020, a related party advanced \$31,734 to the Company that carries no interest nor a maturity date.

NOTE 6 - THIRD PARTY NOTES PAYABLE

All remaining notes payable were written off, including accrued interest at December 31, 2019. The Statute of limitations in Florida is 5 years after the last payment made by the debtor. The last payment made on any of the then remaining debt was greater than 5 years prior to year end 2019.

NOTE 7 – STOCKHOLDERS EQUITY (DEFICIT)

At June 30, 2020 and December 31, 2019, the Company has 1,100,000,000 shares of par value \$0.001 common stock authorized and 322,800,327 issued and outstanding. At June 30, 2020 and December 31, 2019, the Company also has 200,000,000 shares of \$0.0001 par value preferred stock and 34,109,750 Series A and 293,000 Series B issued and outstanding. The preferred shares have the following respective rights and privileges:

Series A carry 10 votes for each share issued and outstanding; is convertible into common stock aggregating 35% of the total issued and outstanding common shares at conversion date; are redeemable for the greater of 45% of the total market value of the common share or the calculation of the book value of the Company made by an independent audit firm or \$5,000,000.

Series B are convertible in common shares of common stock at a conversion price of \$0.0075 per share; is redeemable at a price of 125% of the purchase price paid for the shares; carry one vote for each share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation.

Connectyx Technologies Holdings Group, Inc.
Notes to Financial Statements
(Unaudited)

NOTE 8 - FINANCIAL INSTRUMENTS

(a) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company relies on cash flows generated from operations, as well as injections of capital through the issuance of the Company's capital stock to settle its liabilities when they become due.

(b) Interest Rate Risk The Company is not exposed to significant interest rate risk due to the short-term maturity of its monetary current assets and current liabilities.